Table 2 Comparisons of the area under the receiver operating characteristic curve (AUC), sensitivity, and specificity of autoantibody isotypes against unmodified and 4-hydroxy-2-nonenal (HNE)-modified peptides in rheumatoid arthritis (RA) patients and osteoarthritis (OA) patients compared to healthy controls (HCs)
Peptides | RA vs. HC | OA versus HC | p value a | ||||
|---|---|---|---|---|---|---|---|
AUC (95%CI) | Sensitivity (95%CI) | Specificity (95%CI) | AUC (95%CI) | Sensitivity (95%CI) | Specificity (95%CI) | ||
IgG anti-CFAH1121−1230 | 0.66 (0.57–0.76) | 63.3% (49.9–75.4) | 51.7% (38.4–64.8) | 0.58 (0.46–0.70) | 60.0% (42.1–76.1) | 60.0% (46.5–72.4) | 0.6844 |
Cutoff (OD450) |  | > 0.24 |  |  | < 0.21 |  |  |
IgG anti-CFAH1121−1230 HNE | 0.71 (0.62–0.80) | 76.7% (64.0–86.6) | 55.0% (41.6–67.9) | 0.52 (0.40–0.64) | 51.4% (34.0–68.6) | 50.0% (36.8–63.2) | 0.0135 |
Cutoff (OD450) |  | > 0.21 |  |  | < 0.20 |  |  |
IgM anti-CFAH1121−1230 | 0.68 (0.59–0.78) | 81.7% (69.6–90.5) | 53.3% (40.0–66.3) | 0.68 (0.58–0.79) | 77.1% (59.9–89.6) | 60.0% (46.5–72.4) | 0.4816 |
Cutoff (OD450) |  | > 0.58 |  |  | > 0.63 |  |  |
IgM anti-CFAH1121−1230 HNE | 0.70 (0.61–0.79) | 85.0% (73.4–92.9) | 41.7% (29.1–55.1) | 0.59 (0.47–0.71) | 80.0% (63.1–91.6) | 36.7% (24.6–50.1) | 0.0421 |
Cutoff (OD450) |  | > 0.24 |  |  | > 0.23 |  |  |
IgG anti-HPT78−108 | 0.67 (0.58–0.77) | 71.7% (58.6–82.6) | 55.0% (41.6–67.9) | 0.53 (0.41–0.65) | 51.4% (34.0–68.6) | 46.7% (33.7–60.0) | 0.3711 |
Cutoff (OD450) |  | > 0.64 |  |  | < 0.64 |  |  |
IgG anti-HPT78−108 HNE | 0.66 (0.57–0.76) | 71.7% (58.6–82.6) | 48.3% (35.2–61.6) | 0.58 (0.46–0.70) | 62.9% (44.9–78.5) | 55.0% (41.6–67.9) | 0.8974 |
Cutoff (OD450) |  | > 0.25 |  |  | < 0.25 |  |  |
IgM anti-HPT78−108 | 0.67 (0.57–0.77) | 71.7% (58.6–82.6) | 56.7% (43.2–69.4) | 0.53(0.40–0.66) | 51.4%(33.9–68.6) | 50.0%(36.8– 63.2) | 0.2823 |
Cutoff (OD450) |  | > 0.30 |  |  | < 0.29 |  |  |
IgM anti-HPT78−108 HNE | 0.89 (0.80–0.93) | 86.7% (75.4–94.1) | 66.7% (53.3–78.3) | 0.58 (0.46–0.69) | 65.7% (47.8–80.9) | 55.0% (41.6–67.9) | < 0.0001 |
Cutoff (OD450) |  | > 0.20 |  |  | > 0.16 |  |  |
IgG anti-IGKC2−19 | 0.72 (0.62–0.81) | 80.0% (67.7–89.2) | 60.0% (46.5–72.4) | 0.59 (0.47–0.70) | 65.7% (47.8–80.9) | 53.3% (40.0–66.3) | 0.1471 |
Cutoff (OD450) |  | > 0.41 |  |  | > 0.37 |  |  |
IgG anti-IGKC2−19 HNE | 0.70 (0.61–0.79) | 78.3% (65.8–87.9) | 56.7% (43.2–69.4) | 0.55 (0.43–0.67) | 65.7% (47.9–80.9) | 50.0% (36.8–63.2) | 0.0917 |
Cutoff (OD450) |  | > 0.45 |  |  | > 0.39 |  |  |
IgM anti-IGKC2−19 | 0.83 (0.75–0.90) | 81.7% (69.6–90.5) | 60.0% (46.5–72.4) | 0.56 (0.44–0.68) | 57.1% (39.4–73.7) | 50.0% (36.8–63.2) | < 0.0001 |
Cutoff (OD450) |  | > 0.61 |  |  | > 0.53 |  |  |
IgM anti-IGKC2−19 HNE | 0.86 (0.79–0.93) | 83.3% (71.5–91.7) | 66.7% (53.3–78.3) | 0.58 (0.46–0.70) | 68.6% (50.7–83.2) | 51.7% (38.4–64.8) | < 0.0001 |
Cutoff (OD450) |  | > 0.37 |  |  | > 0.32 |  |  |
IgG anti-THRB328−345 | 0.70 (0.61–0.79) | 66.7% (53.3–78.3) | 53.3% (40.0–66.3) | 0.53 (0.42–0.65) | 62.9% (44.9–78.5) | 48.3% (35.2–61.6) | 0.0086 |
Cutoff (OD450) |  | > 0.20 |  |  | > 0.19 |  |  |
IgG anti-THRB328−345 HNE | 0.75 (0.67–0.84) | 80.0% (67.7–89.2) | 53.3% (40.0–66.3) | 0.60 (0.48–0.71) | 68.6% (50.7–83.2) | 50.0% (36.8–63.2) | 0.0087 |
Cutoff (OD450) |  | > 0.32 |  |  | > 0.31 |  |  |
IgM anti-THRB328−345 | 0.63 (0.53–0.73) | 63.3% (50.0–75.4) | 53.3% (40.0–66.3) | 0.56 (0.44–0.68) | 60.0% (42.1–76.1) | 53.3% (40.0–66.3) | 0.5845 |
Cutoff (OD450) |  | > 0.61 |  |  | > 0.60 |  |  |
IgM anti-THRB328−345 HNE | 0.78 (0.69–0.86) | 76.7% (64.0–86.6) | 71.7% (58.6–82.6) | 0.56 (0.44–0.68) | 65.7% (47.8–80.9) | 46.7% (33.7–60.0) | 0.0001 |
Cutoff (OD450) |  | > 0.64 |  |  | > 0.52 |  |  |